Taken together, these observations show that concomitant genetic SHOC2 inhibition potentiates the cytotoxic properties of MEKi’s in a BIM-dependent manner and increases antitumor efficacy in lung cancer cell lines. Here, BCL2L11 is linked to lung carcinoma.